Share This Article:

From insulin detemir to glargine: Effect on glycemic control and psychological wellbeing in patients with diabetes mellitus type 2 in daily practice

Abstract Full-Text HTML Download Download as PDF (Size:215KB) PP. 101-108
DOI: 10.4236/jdm.2012.21016    4,957 Downloads   8,566 Views   Citations

ABSTRACT

The success of a specific treatment is traditionally judged according to parameters such as HbA1c. However, other, patient-reported outcomes (PRO) of (insulin) therapy, become increasingly more important. The introduction of (basal) insulin-analogues could possibly improve PRO, particularly “quality of life”. Direct comparative studies between once daily insulin glargine and once to twice or twice daily insulin detemir have previously shown differences in insulin dosage, dosing frequency and weight gain. Whether this leads to a difference in quality of life in patients who are transferred from insulin detemir to insulin glargine remains to be determined. To establish the effect of insulin glargine on quality of life and patient satisfaction in patients with DM2 who are in poor metabolic control with a (human) basal insulin, a large prospective, observational study in Dutch daily practice was performed. The results of the patient population switched from NPH-insulin to insulin glargine have been published previously. In this article the results of the group of patients treated with insulin detemir before the observation period are described. The results of this observational study show that changing basal insulin therapy to insulin glargine in patients with DM2 who are in poor glycemic control with insulin detemir leads to a clinically significant improvement of glycemic control as well as emotional wellbeing, despite a small increase in weight. Whether other factors such as decreased dosing frequency play a role remains to be determined by future studies.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Veneman, T. , Storms, F. , Eland, I. and Bouter, P. (2012) From insulin detemir to glargine: Effect on glycemic control and psychological wellbeing in patients with diabetes mellitus type 2 in daily practice. Journal of Diabetes Mellitus, 2, 101-108. doi: 10.4236/jdm.2012.21016.

References

[1] Heine, R.J., et al. (2006) Management of hyperglycaemia in type 2 diabetes. British Medical Journal, 333, 1200-1204. doi:10.1136/bmj.39022.462546.80
[2] Cook, M.N., et al. (2005) Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care, 28, 995-1000. doi:10.2337/diacare.28.5.995
[3] Holman, R., et al. (2008) Intensive glucose control in type 2 diabetes. New England Journal of Medicine, 359, 1577-1589. doi:10.1056/NEJMoa0806470
[4] Rutten, G.E.H.M., et al. (2006) NHG-standaard diabetes mellitus type 2. Huisarts en Wetenschap, 49, 137-152.
[5] Nathan, D., et al. (2009) Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetologia, 52, 17-30. doi:10.1007/s00125-008-1157-y
[6] Rubino, A., et al. (2007) Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: A population-based analysis in the UK. Diabetic Medicine, 24, 1412-1418. doi:10.1111/j.1464-5491.2007.02279.x
[7] Cook, M., et al. (2007) Initial monotherapy with either metformin or sulphonylureas often fails to achieve maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabetic Medicine, 24, 350-358. doi:10.1111/j.1464-5491.2007.02078.x
[8] Korytkowski, M. (2002) When oral agents fail: Practical barriers to starting insulin. International Journal of Obesity, 26, S18-S24. doi:10.1038/sj.ijo.0802173
[9] Peyrot, M., et al. (2005) Resistance to insulin therapy among patients and providers: Results of the cross-sectional Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care, 28, 2673-2679. doi:10.2337/diacare.28.11.2673
[10] Tabaei, B.P., et al. (2004) Glycemia and the quality of well-being in patients with diabetes. Quality of Life Research, 13, 1153-1161. doi:10.1023/B:QURE.0000031336.81580.52
[11] Rubin, R. (2005) Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. American Journal of Medicine, 118, 27S-24S. doi:10.1016/j.amjmed.2005.04.012
[12] Lundkvist, J., et al. (2005) The economic and quality of life impact of hypoglycemia. European Journal of Health Economics, 6, 197-202.
[13] Cryer, P.E. and Childs, B.P. (2002) Negotiating the barrier of hypoglycemia in diabetes. Diabetes Spectrum, 15, 20-27. doi:10.2337/diaspect.15.1.20
[14] Polonsky, W., et al. (2005) Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem. Diabetes Care, 28, 2543-2545. doi:10.2337/diacare.28.10.2543
[15] Wilson, M., et al. (2004) Treatment satisfaction after commencement of insulin in type 2 diabetes. Diabetes Research and Clinical Practice, 66, 263-267. doi:10.1016/j.diabres.2004.04.010
[16] Houlden, R., et al. (2007) Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of type 2 diabetes: The Canadian INSIGHT study. Diabetes Research and Clinical Practice, 78, 254-258. doi:10.1016/j.diabres.2007.03.021
[17] Vinik, A., et al. (2007) Adding insulin glargine versus rosiglitazone. Health-related quality of life impact in type 2 diabetes. Diabetes Care, 30, 795-800. doi:10.2337/dc06-1712
[18] Hajos, T., et al. (2011) Initiation of insulin glargine in patients with type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care. Diabetic Medicine, 28, 1096-1102. doi:10.1111/j.1464-5491.2011.03329.x
[19] De Grauw, W.J.C., et al. (2001) Insulin therapy in poorly controlled type 2 diabetic patients: Does it affect quality of life? British Journal of General Practice, 51, 527-532.
[20] De Sonnaville, J.J., et al. (1998) Well-being and symptoms in relation to insulin therapy in type 2 diabetes. Diabetes Care, 21, 919-924. doi:10.2337/diacare.21.6.919
[21] Redekop, W., et al. (2002) Health-related quality of life and treament satisfaction in Dutch patients with type 2 diabetes. Diabetes Care, 25, 458-463. doi:10.2337/diacare.25.3.458
[22] Goddijn, P., et al. (1999) Longitudinal study on glycaemic control and quality of life in patients with type 2 diabetes mellitus referred for intensified control. Diabetes Medicine, 16, 23-30. doi:10.1046/j.1464-5491.1999.00002.x
[23] Davis, T., et al. (2001) Effect of insulin therapy on quality of life in type 2 diabetes mellitus: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 52, 63-71. doi:10.1016/S0168-8227(00)00245-X
[24] Horvath, K., et al. (2007) Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, 2, CD005613.
[25] Hajos, T., et al. (2009) Switching from NPH to insulin glargine positively impacts on glycemic control and psychological well-being in suboptimally controlled type 2 diabetes patients. An observational study. Diabetes, 58, A537
[26] Snoek, F.J., et al. (1996) The Dutch version of the hypoglycemia fear survey: Internal consistency and validity. Gedrag en Gezondheid, 24, 287-292.
[27] Grootenhuis, P., et al. (1994) Development of a type 2 diabetes symptom checklist: A measure of symptom severity. Diabetic Medicine, 11, 253-261. doi:10.1111/j.1464-5491.1994.tb00268.x
[28] Arbuckle, R., et al. (2009) Psychometric evaluation of the Diabetes Symptom Checklist-Revised (DSC-R)-A Measure of Symptom Distress. Value Health, 12, 1168-1175. doi:10.1111/j.1524-4733.2009.00571.x
[29] Bech, P., et al. (1996) The WHO (Ten) Well-Being Index: Validation in diabetes. Psychotherapy and Psychosomatics, 65, 183-190. doi:10.1159/000289073
[30] Lowe, B., et al. (2004) Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians’ diagnoses. Journal of Affective Disorders, 78, 131-140. doi:10.1016/S0165-0327(02)00237-9
[31] Rubin, D.B. (1987) Multiple imputation for nonresponse in surveys. John Wiley & Sons, New York. doi:10.1002/9780470316696
[32] Rosenstock, J., et al. (2005) Reduced hypoglycemia risk with insulin glargine. A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care, 28, 950-955. doi:10.2337/diacare.28.4.950
[33] Mullins, P., et al. (2007) Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with Neutral Protamine Hagendorn insulin in type 1 and type 2 diabetes mellitus. Clinical Therapeutics, 29, 1607-1619. doi:10.1016/j.clinthera.2007.08.020
[34] Hermansen, K., et al. (2006) A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care, 29, 1269-1274. doi:10.2337/dc05-1365
[35] Rossetti, P., et al. (2008) Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. Archives of Physiology and Biochemistry, 114, 3-10. doi:10.1080/13813450801900777
[36] Rosenstock, J., et al. (2008) A randomised, 52 week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia, 51, 408-416. doi:10.1007/s00125-007-0911-x
[37] Swinnen, S., et al. (2010) A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled in oral glucose-lowering drugs. Diabetes Care, publish ahead of print, published online March 3, 2010.
[38] Hollander, P., et al. (2008) A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clinical Therapeutics, 30, 1976-1987. doi:10.1016/j.clinthera.2008.11.001
[39] Raskin, P., et al. (2009) Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 25, 542-548. doi:10.1002/dmrr.989
[40] Swinnen, S., et al. (2011) Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, 7, CD006383. doi:10.1002/14651858.CD006383.pub2
[41] Swinnen, S., et al. (2009) Higher dose requirements with insulin detemir in type 2 diabetes—Three cases and a review of the literature. Diabetes Research and Clinical Practice, 84, e24-e26. doi:10.1016/j.diabres.2009.02.009
[42] Morris, A.D. (2003) Addressing dosing frequency in diabetes: A simple approach to improving adherence to therapy and clinical outcomes. Diabetes Educator, 29, 440-446. doi:10.1177/014572170302900309
[43] Hajos, T., et al. (2011) Modest weight gain following insulin glargine initiation is not associated with decreased health-related quality of life (HRQoL) in type 2 diabetes. Diabetes, 60, A229.
[44] Bech, P., Olsen, L.R., Kjoller, M. and Rasmussen, N.K. (2003) Measuring well-being rather than the absence of distress symptoms: A comparison of the SF-36 mental health subscale and the WHO-five well-being scale. International Journal of Methods in Psychiatric Research, 12, 85-91. doi:10.1002/mpr.145

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.